We repurposed the antifibrotic drug pirfenidone-which is approved for treatment of idiopathic lung fibrosis-in a series of patients with nonalcoholic steatohepatitis-related cirrhosis. Our report demonstrates the observed improvements in necroinflammation and regression of cirrhosis with pirfenidone use for 12-weeks, associated with classical hepatic repair complex features on follow-up liver biopsies. This novel work could help stimulate further randomized trials of pirfenidone in patients with nonalcoholic steatohepatitis-related liver fibrosis or cirrhosis, for whom no recommended drug treatments exists currently.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC7132022 | PMC |
| http://dx.doi.org/10.14218/JCTH.2019.00056 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Severe Reversible Heart Failure Enhanced by Sorafenib Treatment for Hepatocellular Carcinoma.
Cureus
January 2025
Medical Oncology, Instituto Português de Oncologia de Coimbra Francisco Gentil, Coimbra, PRT.
The multitarget oral tyrosine kinase inhibitor sorafenib is an effective first-line treatment option in unresectable hepatocellular carcinoma. Through its mechanism of action, it has been associated with cardiotoxicity, mainly hypertension, which is usually low-grade and well-managed with behavioral changes and antihypertensor treatment adjustment, if needed. Acute, symptomatic heart failure is rarely described.
View Article and Find Full Text PDFMechanism Study of Xiaoyao San against Nonalcoholic Steatohepatitis-Related Liver Fibrosis Based on a Combined Strategy of Transcriptome Analysis and Network Pharmacology.
Pharmaceuticals (Basel)
August 2024
Medical Systems Biology Research Center, School of Medicine, Tsinghua University, Beijing 100084, China.
Nonalcoholic fatty liver disease (NAFLD) is the leading cause of liver disease worldwide. Nonalcoholic steatohepatitis (NASH) is an advanced form of NAFLD. The livers of patients with NASH are more likely to develop fibrosis.
View Article and Find Full Text PDFVisceral Fat Associated with Worsening of Recurrent Esophageal Varices in Alcoholic/Nonalcoholic Steatohepatitis-Related Liver Cirrhosis.
J Nippon Med Sch
September 2024
Department of Surgery, Tokyo Women's Medical University Adachi Medical Center.
Background: Alcoholic steatohepatitis and nonalcoholic steatohepatitis-related liver cirrhosis (ASH/NASH-LC) are major causes of esophageal varices (EVs). However, the association between high visceral fat and exacerbation of EVs remains unclear. The aim of this study was to clarify the association of visceral fat and recurrence rate of EVs in ASH/NASH-LC and to identify independent predictors associated with recurrence.
View Article and Find Full Text PDFSurgical Implications for Nonalcoholic Steatohepatitis-Related Hepatocellular Carcinoma.
Cancers (Basel)
August 2024
Department of Surgery, Baylor College of Medicine, Houston, TX 77030, USA.
Hepatocellular carcinoma (HCC) is an aggressive form of liver cancer that arises in a background of chronic hepatic injury. Metabolic syndrome-associated fatty liver disease (MAFLD) and its severe form, nonalcoholic steatohepatitis (NASH), are increasingly common mechanisms for new HCC cases. NASH-HCC patients are frequently obese and medically complex, posing challenges for clinical management.
View Article and Find Full Text PDFmA-mediated lnc-OXAR promotes oxaliplatin resistance by enhancing Ku70 stability in non-alcoholic steatohepatitis-related hepatocellular carcinoma.
J Exp Clin Cancer Res
July 2024
State Key Laboratory of Oncology in South China and Collaborative Innovation Center for Cancer Medicine, Sun Yat-Sen University Cancer Center, Guangzhou, China.
Background: The escalating prevalence of metabolic diseases has led to a rapid increase in non-alcoholic steatohepatitis (NASH)-related hepatocellular carcinoma (NASH-HCC). While oxaliplatin (OXA)-based hepatic arterial infusion chemotherapy (HAIC) has shown promise in advanced-stage HCC patients, its efficacy in NASH-HCC remains uncertain. This study aims to assess the effectiveness of OXA-based HAIC and elucidate the mechanisms underlying OXA resistance in NASH-HCC.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!